FSD Pharma Inc
CNSX:HUGE
FSD Pharma Inc
EPS (Diluted)
FSD Pharma Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
FSD Pharma Inc
CNSX:HUGE
|
EPS (Diluted)
-$1
|
CAGR 3-Years
30%
|
CAGR 5-Years
-119%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
47%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
EPS (Diluted)
-$1
|
CAGR 3-Years
6%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-6%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
FSD Pharma Inc
Glance View
FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. The company is headquartered in Toronto, Ontario and currently employs 10 full-time employees. The company went IPO on 2018-05-29. The Company, through its subsidiary, FSD Biosciences Inc., is focused on pharmaceutical research and development (R&D) of its lead compound, FSD 201, ultra-micronized Palmitoyl (PEA). FSD 201 stabilizes mast cells of the human body and down-regulate the proinflammatory cytokines to effectuate an anti-inflammatory response. Lucid Psycheceuticals Inc., a subsidiary of the Company, has worldwide rights to compounds shown to prevent and reverse the biochemical mechanisms of progressive multiple sclerosis in multiple preclinical animal models. Additionally, the Company is focused on develop a psychoactive (psychedelic-based) therapeutic of neurodegenerative disorders.
See Also
What is FSD Pharma Inc's EPS (Diluted)?
EPS (Diluted)
-1
USD
Based on the financial report for Dec 31, 2021, FSD Pharma Inc's EPS (Diluted) amounts to -1 USD.
What is FSD Pharma Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-119%
Over the last year, the EPS (Diluted) growth was 62%. The average annual EPS (Diluted) growth rates for FSD Pharma Inc have been 30% over the past three years , -119% over the past five years .
